Company Filing History:
1 out of 504 
1 out of 81 Years Active: 2013
Title: The Innovations of Stephen Bornemann
Introduction
Stephen Bornemann is an accomplished inventor based in Norwich, GB. He has made significant contributions to the field of biotechnology, particularly in the development of methods for determining chemotherapeutic agents. His work focuses on targeting alpha-glucan pathways, which has important implications for antibacterial treatments.
Latest Patents
Stephen Bornemann holds a patent titled "Methods for determining chemotherapeutic agents targeting alpha-glucan pathways and uses thereof." This invention provides methods for determining a putative antibacterial, which includes assessing whether the putative antibacterial inhibits GlgE or Rv3032. The patent also encompasses the antibacterial itself, a pharmaceutical composition, and methods for treating subjects infected with bacteria through the administration of the antibacterial.
Career Highlights
Throughout his career, Stephen has worked with notable institutions such as the Albert Einstein College of Medicine and Plant Bioscience Limited. His experience in these organizations has allowed him to advance his research and contribute to the scientific community.
Collaborations
Stephen has collaborated with esteemed colleagues, including William R Jacobs, Jr. and Rainer Kalscheuer. These partnerships have enriched his work and expanded the impact of his inventions.
Conclusion
Stephen Bornemann's innovative approaches to antibacterial treatments highlight his expertise and dedication to advancing medical science. His contributions continue to influence the field and pave the way for future developments.